ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
DNA blotting analysis of 64 tumors indicates that trisomy 12 does not seem to be related to K-ras-2 amplification in ovarian tumors.
|
2071229 |
1991 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
|
8319218 |
1993 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations.
|
9115967 |
1997 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
|
10078924 |
1999 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
K-RAS mutations are the most frequent molecular genetic alteration in serous ovarian tumors of borderline malignancy (SBOT).
|
12594239 |
2003 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The TOV-21G, TOV-81D, OV-90, and TOV-112D cell lines were derived from ovarian tumors (TOV) or ascites (OV) from chemotherapy- and radiotherapy-naive patients and were characterized by their mutation spectrum of BRCA2, TGFbeta-RII, KRAS2, TP53, and CDKN2A.
|
15258697 |
2004 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that an activated MAPK pathway is critical in tumor growth and survival of ovarian tumors with KRAS or BRAF mutations and suggest that the CI-1040 induced phenotypes depend on the mutational status of KRAS and BRAF in ovarian tumors.
|
15753399 |
2005 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
|
15842656 |
2005 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
|
17910045 |
2008 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The identical KRAS mutation was detected in all of the analyzed components of the primary ovarian tumors in 4 cases.
|
18779727 |
2008 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Profound growth inhibition and apoptosis were observed in CI-1040-treated cancer cells with mutations in either KRAS or BRAF in comparison with the ovarian cancer cells containing wild-type sequences.
|
19018267 |
2008 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Profound growth inhibition and apoptosis were observed in CI-1040-treated cancer cells with mutations in either KRAS or BRAF in comparison with the ovarian cancer cells containing wild-type sequences.
|
19018267 |
2008 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We found no evidence of disease association for SNPs in BRAF, KRAS, ERBB2 and PIK3CA when OC was considered as a single disease phenotype; but after stratification by histological subtype, we found borderline evidence of association for SNPs in KRAS and BRAF with mucinous OC and in ERBB2 and PIK3CA with endometrioid OC.
|
19240718 |
2009 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the KRAS gene in ovarian tumors.
|
19995707 |
2009 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings strongly support the hypothesis that the KRAS-variant is a genetic marker for increased risk of developing OC, and they suggest that the KRAS-variant may be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities.
|
20647319 |
2010 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
|
21372221 |
2011 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility.
|
21385923 |
2011 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
|
21975775 |
2011 |